Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30309026 | 0.83 | KMT2A (0.37) | ALDH1A1KDM4EPOLBL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL5340879 | 0.82 | CTBP2 (0.41) | ALDH1A1KDM4EKMT2ANPSR1TAAR1 | |
| SCHEMBL12641536 | 0.81 | TAAR1 (0.44) | ALDH1A1KDM4EPOLBL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL9735062 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4EPOLBL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL2823143 | 0.80 | IDO1 (0.45) | ALDH1A1KDM4EPOLBKMT2AIDO1 | |
| Hydrochloric Acid SCHEMBL5342849 | 0.79 | ALDH1A1 (0.44) | ALDH1A1KDM4EL3MBTL1KMT2AIDO1 | |
| Hydrochloric Acid SCHEMBL5352081 | 0.79 | POLQ (0.48) | ALDH1A1KDM4EKMT2AIDO1MEN1 | |
| Hydrochloric Acid SCHEMBL6406497 | 0.78 | LMNA (0.49) | ALDH1A1POLBKMT2AIDO1TAAR1 | |
| Hydrochloric Acid SCHEMBL26611579 | 0.78 | PYCR1 (0.38) | KDM4EKMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL31053374 | 0.77 | L3MBTL1 (0.60) | ALDH1A1KDM4EPOLBL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-11-07 | — | — | US | disclosed |
| EP-4396181-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | Breye Therapeutics ApS (DK) | 2024-07-10 | — | — | EP | disclosed |
| CN-117881675-A | 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists | 布雷耶疗法有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023031319-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | AXXAM S.P.A. (IT) | 2023-03-09 | — | — | WO | disclosed |
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | CARROLL WILLIAM A | 2007-10-04 | — | — | US | disclosed |
| US-7241776-B2 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2006017406-A1 | CYANOAMIDINE P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBVIE INC. | 2006-02-02 | — | — | US | disclosed |
| EP-0402096-B1 | Anticonvulsant pyrazines | WELLCOME FOUND (GB) | 1996-08-21 | — | — | EP | disclosed |
| US-5095018-A | Anticonvulsants | BURROUGHS WELLCOME CO. (US) | 1992-03-10 | — | — | US | disclosed |
| EP-0402096-A2 | Anticonvulsant pyrazines | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | P2RX2, P2RX1, P2RX7 | GAA 4220/4885ALDH1A1 3848/4885KDM4E 3687/4885 |
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | P2RX2, P2RX1, P2RX7 | GAA 4220/4885ALDH1A1 3848/4885KDM4E 3687/4885 |
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | P2RX3, P2RX7, P2RX2 | GAA 3011/4885ALDH1A1 1602/4885KDM4E 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.